New clotting factor shows promise for hemophilia a bleeding control
NCT ID NCT06297655
First seen Jun 20, 2026 · Last updated Jun 20, 2026
Summary
This phase 3 trial tests a lab-made clotting factor (factor VIII) in 60 people with severe hemophilia A. The goal is to see if it safely stops bleeding when needed and works well during surgeries. Participants receive the drug on demand for new bleeds or before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, 230002, China
-
Fuyang Hospital Affiliated to Anhui Medical University
Fuyang, Anhui, 236000, China
-
Hematology Hospital of Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Henan Tumor Hospital
Zhengzhou, Henan, 450003, China
-
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, 330006, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
-
Nanjing Drug Tower Hospital
Nanjing, Jiangsu, 210008, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
-
The First Hospital of Lanzhou University
Lanzhou, Gansu, 730013, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400010, China
-
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650106, China
-
Xiangya Hospital Central South University
Changsha, Hunan, 410008, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human coagulation factor VIII
What this could lead to
If successful, this could provide a safe and effective on-demand treatment for bleeding episodes and surgical support in severe hemophilia A.
What could go wrong
This is a single-arm, open-label trial with only 60 participants, so results may not apply broadly. The treatment is not a cure and requires ongoing use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.